

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An isolated polypeptide that specifically binds to a neoplastic cell or a cell of a pre-cancerous lesion, but does not specifically bind to a normal cell, wherein said isolated polypeptide comprises amino acids 28-32, 51-53, and 90-100 of the sequence of ~~SEQ ID NO:27~~ SEQ ID NO:29, and wherein said normal cell is not a cell of the glomerular, fascicular zone of the adrenal gland or an epithelial cell of the collection tubes of the kidney.

2. (Currently Amended) The isolated polypeptide of claim 1, wherein said polypeptide further comprises amino acids 11-18, 36-43, and 82-104 of the sequence of ~~SEQ ID NO:26~~ SEQ ID NO:28.

3-4. (Cancelled)

5. (Currently Amended) The isolated polypeptide of claim 1 ~~or 3~~, wherein said polypeptide is capable of inducing apoptosis of said neoplastic cell or said cell of said pre-cancerous lesion, but does not induce apoptosis of said normal cell.

6. (Currently Amended) The isolated polypeptide of claim 1 ~~or 3~~, wherein said neoplastic cell is selected from the group consisting of Barrett's tumors and tumors of the

esophagus, stomach, intestine, rectum, liver, gallbladder, pancreas, lungs, bronchi, breast, cervix, prostate, heart, ovary, and uterus.

7. (Currently Amended) The isolated polypeptide of claim 1 ~~or 3~~, wherein said pre-cancerous lesion is selected from the group consisting of dysplasia of the gastric mucosa, interstitial metaplasia of the stomach, inflammation of the gastric mucosa which is associated with the bacteria *Helicobacter pylori*, tubular and tubulovillous adenomas of the stomach, tubular adenoma of the colon, villous adenoma of the colon, dysplasia in ulcerative colitis, Barrett's dysplasia, Barrett's metaplasia of the esophagus, cervical intraepithelial neoplasia I, cervical intraepithelial neoplasia II, cervical intraepithelial neoplasia III, squamous epithelial metaplasia, squamous epithelial dysplasia of the bronchus, low grade and high grade prostate intraepithelial neoplasia (PIN), breast ductal carcinoma in situ (D-CIS), and breast lobular carcinoma in situ (L-CIS).

8. (Currently Amended) The isolated polypeptide of claim 1 ~~or 3~~, wherein said polypeptide is a functional fragment of an antibody selected from the group consisting of V_L, V_H, F_V, F_C, Fab, Fab', and F(ab')₂.

9. (Currently Amended) The isolated polypeptide of claim 1 ~~or 3~~, wherein said polypeptide specifically binds to a polypeptide comprising the sequence of SEQ ID NO:6.

10. (Currently Amended) An isolated nucleic acid molecule comprising nucleic acids 31-54, 106-129, and 244-312 of the sequence of ~~SEQ ID NO:28~~ SEQ ID NO:26, and/or 82-96, 151-159, and or 268-300 of the sequence of ~~SEQ ID NO:29~~ SEQ ID NO:27.

11. (Cancelled)

12. (Cancelled)

13. (Currently Amended) A vector comprising the nucleic acid sequence of ~~SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:28~~ SEQ ID NO:26, or ~~SEQ ID NO:29~~ SEQ ID NO:27.

14. (Original) An isolated cell comprising the vector of claim 13.

15-57. (Cancelled)